Escitalopram Neuroimaging Supplement

Status Completed

Clinical Trial Summary

The purpose of this study is to find out more about the brain's response to selective serotonin reuptake inhibitor (SSRIs) treatment in people with body dysmorphic disorder (BDD). The investigators will use positron emission tomography (PET) and Magnetic Resonance Imaging (MRI) scans to look at brain activity in people with BDD before and after treatment with an SSRI. The investigators hope that what is learned will allow prediction of whether someone will improve with SSRI treatment.

Clinical Trial Description

The investigators have chosen to focus on five regions of interest, namely ACC, OFC, caudate, amygdala and hippocampus. These are brain regions that have been previously associated with obsessive-compulsive, affective, and psychotic phenomena. The investigators will test for correlations between pre-treatment FDG brain images and subsequent SSRI treatment outcome to identify potential predictors of treatment response. Finally, the investigators will compare pre-treatment and post-treatment PET FDG studies as well as MRI studies in BDD subjects to examine changes in these brain regions following treatment. The goals of the proposed research are to use FDG-PET and MRI to identify predictors of treatment response to SSRIs in BDD and to determine changes in rCMRglu in BDD subjects following treatment with SSRIs. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01398865
Study type	Observational
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	N/A
Start date	December 2008
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02635152` - Interpretation Bias Modification for Body Dysmorphic Disorder	N/A
Completed	`NCT03673046` - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)	N/A
Recruiting	`NCT05402475` - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder	N/A
Withdrawn	`NCT02843451` - Milk Thistle in Body Dysmorphic Disorder	Phase 2
Completed	`NCT02010619` - Internet Delivered CBT for Body Dysmorphic Disorder	N/A
Completed	`NCT00842309` - D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder	Early Phase 1
Completed	`NCT00245635` - Fluoxetine in Pediatric Body Dysmorphic Disorder	Phase 4
Completed	`NCT02808702` - Brain Correlates of Self-Focused Processing	N/A
Completed	`NCT01002326` - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder	N/A
Active, not recruiting	`NCT01075672` - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals	N/A
Completed	`NCT02671266` - Oxytocin Administration in BDD and OCD	Phase 2
Completed	`NCT01038128` - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder	N/A
Completed	`NCT00265109` - Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder	Phase 4
Recruiting	`NCT04373629` - Perceptual Abnormalities and Their Malleability in BDD	N/A
Completed	`NCT01453439` - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder	N/A
Completed	`NCT00871143` - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)	N/A
Completed	`NCT00106223` - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder	N/A
Active, not recruiting	`NCT00211809` - CBT as an Adjunct to SRIs in the Treatment of BDD	Phase 4